BlossomHill Therapeutics, Inc. BLSM
14.74 USD -1.38 (-8.56%)
Nov 12, 2026, 10:16 AM EST
14.51 Day range 16.08
11.02 52-week range 27.99
- YTD
- -7.87%
- 1 year
- -7.87%
News
benzinga.com BlossomHill Therapeutics Announces Alignment With FDA On 50mg Twice Daily As Recommended Phase 2 Dose For BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027
globenewswire.com BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Alignment with the US Food and Drug Administration on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational…
benzinga.com BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…
benzinga.com BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027 Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND…
benzinga.com Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40 Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.- benzinga.com Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40 Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
benzinga.com Earnings Scheduled For September 18, 2026 Companies Reporting Before The Bell • BlossomHill Therapeutics (NASDAQ:BLSM) is expected to report earnings for its second quarter. Companies Reporting After The Bell This article was generated by…
benzinga.com BlossomHill Therapeutics Q2 EPS $(8.75) BlossomHill Therapeutics (NASDAQ:BLSM) reported quarterly losses of $(8.75) per share. This is a 58.8 percent decrease over losses of $(5.51) per share from the same period last year.
benzinga.com BlossomHill Therapeutics Announces Updated Data From Ongoing Phase 1/2 SOLARA Trial Of BH-30643 In NSCLC Patients With Secondary EGFR Resistance Mutations Such As EGFR C797S 45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat…- benzinga.com LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32 LifeSci Capital initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $32.
- benzinga.com Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36 Leerink Partners initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $36.
- benzinga.com JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28 JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.
- benzinga.com Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30 Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.
benzinga.com This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com HC Wainwright & Co. Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $35 HC Wainwright & Co. analyst Robert Burns initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $35.- benzinga.com Blossomhill Says FDA Grants Fast Track Designation To BH-30643 For Treatment Of Adult Patients With Advanced Or Metastatic EGFR C797S-Positive NSCLC After Prior Treatment With Third-Gen EGFR Tyrosine Kinase Inhibitor BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…